Complete Omics Inc. is pleased to share that our founder and CEO, Dr. Qing Wang, has been featured on the official website of the Wharton School of the University of Pennsylvania, one of the world’s leading institutions for business education and leadership development.
Read the full feature here: Wharton Empowering Entrepreneurs – Qing Wang’s Story.
For more than a century, Wharton has played an important role in educating leaders across industries, including healthcare, biotechnology, and life sciences. Its alumni community includes many distinguished figures in the global healthcare sector, such as Leonard Schleifer, founder and CEO of Regeneron Pharmaceuticals, and Alex Gorsky, former Chairman and CEO of Johnson & Johnson.
Dr. Qing Wang, Founder and CEO of Complete Omics, commented:
“It is a great honor to be featured by Wharton,” said Dr. Wang. “My experience at Wharton reinforced the importance of connecting scientific innovation with entrepreneurial leadership. At Complete Omics, we believe that deeper molecular insights can transform how diseases are understood, detected, and ultimately treated. Wharton has educated many leaders whose work has helped shape industries and improve the world, and many Wharton alumni have long been role models for me. Leaders such as Elon Musk, Leonard Schleifer, and Alex Gorsky demonstrate how bold vision and disciplined execution can drive meaningful progress. Their examples continue to inspire us as we build technologies at Complete Omics aimed at advancing biomedical research and improving patient care.”
The Wharton feature highlights Dr. Wang’s professional journey combining scientific research and entrepreneurship. Before founding Complete Omics, Dr. Wang spent many years conducting research in molecular diagnostics and cancer biology, including work at Johns Hopkins University School of Medicine, where he contributed to studies in cancer genomics and molecular diagnostics.
Building on this scientific background, Dr. Wang founded Complete Omics Inc. with the goal of advancing multi-omics technologies that can help deepen our understanding of human biology and disease. Today, the company develops integrated platforms combining proteomics, metabolomics, genomics, and computational analytics to support biomarker discovery, translational research, and precision medicine.
Dr. Wang’s experience at Wharton further strengthened the company’s strategic development by bringing together scientific innovation with business leadership. The recognition from Wharton reflects both Dr. Wang’s academic and entrepreneurial background as well as the growing importance of interdisciplinary approaches in biotechnology innovation.
Complete Omics is grateful to its collaborators, partners, and team members who have contributed to the company’s progress. We remain committed to advancing next-generation multi-omics technologies and supporting research and clinical efforts aimed at improving human health.
